General description
Native, human C8 complement component. Glycoprotein composed of three non-identical subunits of M.W. 64 kDa (α), 64 kDa (β), and 22 kDa (γ). Present in normal human serum at 55 µg/ml. On activation of complement via either the classical or alternative pathway, C5 is cleaved into C5a and C5b fragments. The nascent C5b fragment binds to C6, C7, and C8 resulting in formation of the C5b-8 complex on target surfaces. Each membrane-bound, hydrophobic C5b-8 complex combines with three to six C9 molecules to complete the assembly of the lytic C5b-9 complement membrane attack complex (MAC).
Native, human C8 complement component. Glycoprotein composed of three non-identical subunits of M.W. 64,000 (α), 64,000 (β), and 22,000 (γ). Present in normal human serum at 55 µg/ml. On activation of complement via either the classical or alternative pathway, C5 is cleaved into C5a and C5b fragments. The nascent C5b fragment binds to C6, C7, and C8, resulting in formation of C5b-8 complex on target surfaces. Each membrane-bound, hydrophobic C5b-8 complex combines with three to six C9 molecules to complete the assembly of the lytic C5b-9 complement membrane attack complex (MAC).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Steckel, E.W., et al. 1980. J. Biol. Chem. 255, 11997.Petersen, B.H., et al. 1976. J. Clin. Invest. 57, 283.
Packaging
250 µg in Plastic ampoule
Please refer to vial label for lot-specific concentration.
Physical form
In PBS, pH 7.2.
Preparation Note
Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Reconstitution
Following initial thaw, aliquot and freeze (-70°C).
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: